In Brief: FDA Anti-Infective Drugs Advisory Committee
Executive Summary
FDA Anti-Infective Drugs Advisory Committee: Will meet July 24 to discuss Mylan's Sulfamylon sulfadiazine cream 1% for treatment of patients with chronic wounds ("The Pink Sheet" May 13, T&G-6). The committee also will discuss Mylan's sulfamylon solution 5% (NDA 19-832) for control of bacterial colonization on excised burn wounds. On July 25-26, the committee will discuss antibiotic resistance issues, including development of FDA policy on agents for multidrug-resistant organisms and labeling issues. FDA is encouraging the submission of comments on development of drugs for multidrug-resistant infections. The meeting will begin at 8:30 a.m. each day at the Holiday Inn in Silver Spring, Md...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth